Drug Profile


Alternative Names: ASP-0113; Cytomegalovirus DNA vaccine bivalent - Vical; TransVax

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vical
  • Developer Astellas Pharma; Vical
  • Class Cytomegalovirus vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus infections
  • New Molecular Entity No

Highest Development Phases

  • Phase III Cytomegalovirus infections

Most Recent Events

  • 12 Oct 2017 Vical completes a phase III trial in Cytomegalovirus infections (Prevention) in USA, Australia, Canada, Germany, Japan, South Korea, Belgium, France, Germany, Spain, Sweden and Taiwan
  • 15 May 2017 Vical announces its intention to file a BLA with the US FDA for Cytomegalovirus infections in 2018
  • 29 Apr 2017 Pharmacokinetics, adverse events and immunogenicity data from a phase I trial in Cytomegalovirus presented at the 2017 American Transplant Congress (ATC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top